NAD+ Precursors for Aging Muscle: Beyond NMN

A compound found in coffee, legumes, and fenugreek is lower in people with sarcopenia—and it reaches NAD+ through a different route than NMN or nicotinamide riboside (NR). That makes trigonelline scientifically interesting. It does not make coffee a treatment for muscle loss.

The larger lesson is more useful: "raises NAD+" is not a single biological claim. Different precursors use different enzymes, reach different tissues, and can raise NAD+ in blood without raising it in skeletal muscle. For people trying to preserve muscle with age, that distinction matters more than a flashy before-and-after blood test.

Trigonelline points to a different NAD+ route

In a 2024 Nature Metabolism study, researchers compared 20 older adults with sarcopenia with 20 healthy age-matched controls. Serum trigonelline was significantly lower in the sarcopenia group, and the association was replicated in the Bushehr elderly health cohort. Across the study cohort, higher serum trigonelline tracked with higher appendicular lean mass index, stronger grip, and faster gait speed—the three measurements used to characterize sarcopenia.

Those are associations, not proof that low trigonelline causes muscle loss or that taking it reverses muscle loss. Diet quality could explain part of the signal; the authors specifically acknowledged potential confounding by factors such as fiber and folate intake. The study also does not report the relevant correlation coefficients or confidence intervals in the available summary, and its discovery comparison was small.

Still, the biology gives the finding a plausible basis. Trigonelline is an N-methylated derivative of nicotinic acid. It enters NAD+ synthesis through the NAPRT-dependent Preiss–Handler pathway, whereas NMN and NR depend on the NRK salvage route. Aged and sarcopenic muscle has lower NAMPT activity, which may make the usual salvage route less effective. That is a hypothesis about tissue context, not a demonstrated human treatment effect.

Matched muscle-biopsy RNA sequencing from 39 samples linked serum trigonelline most strongly with mitochondrial oxidative-phosphorylation pathways, with an enrichment false-discovery rate below 10⁻²⁰. Serum trigonelline also correlated with intramuscular NAD+. Neither result establishes that trigonelline repaired mitochondria; both make it a reasonable target for intervention studies.

Cell data are encouraging, but they are still cell data

In primary human skeletal-muscle myotubes, trigonelline raised NAD+ with an EC₅₀ of 315 μM under ordinary conditions. When researchers blocked NAMPT with FK866 to model the NAMPT-deficient setting, the EC₅₀ fell to 110 μM. In this assay, trigonelline therefore worked at a lower concentration when NAMPT was blocked. Primary myotubes from 22-month-old mice, with 8–9 biological replicates, also showed target engagement.

That pattern supports the pathway argument, but it leaves the practical question unanswered: no published human pharmacokinetic or intervention trial has shown that oral trigonelline reaches those concentrations, raises muscle NAD+, or improves strength, gait speed, or lean mass. The mammalian enzyme that converts trigonelline to nicotinic acid has not been identified. Coffee is a pleasant beverage, not a completed clinical trial.

Trigonelline may have one pharmacokinetic advantage worth testing. It remained stable in human serum for 72 hours in the comparative experiment, while NR and NMN converted rapidly to nicotinamide within hours. Yet in the same cell system, NR and NMN increased NAD+ about twofold, versus roughly 50% for trigonelline and nicotinamide. Tissue access may matter more than maximal cell-culture potency, but no human head-to-head trial has settled that trade-off.

Nicotinamide plus vitamin B6: a stem-cell lead, not a regimen

A separate 2024 JCI study screened more than 50,000 natural bioactive compounds and plant extracts in primary human myogenic progenitors. Of 534 hits that increased PAX7⁻MYOD⁺ cells by more than 15%, nicotinamide (NAM) and pyridoxine (vitamin B6) stood out among compounds already approved or generally recognized as safe.

At 110 μM, each increased MYOD⁺ progenitors by about 35%. The compounds acted differently: NAM activated CK1/β-catenin signaling and increased proliferating PAX7⁺Ki67⁺ stem cells, while pyridoxine activated AKT and protein-synthesis pathways that promoted differentiation without increasing proliferation. Together, they regulated 630 additional genes compared with either compound alone, improved the maximal response and EC₅₀ for MYOD⁺ induction, enhanced myotube maturation, and preserved reserve PAX7⁺ cells after differentiation.

That is unusually thoughtful preclinical work, and circulating NAM and bioactive pyridoxine were lower in older people with lower muscle mass and function. It is not evidence that an older adult should combine over-the-counter NAM and B6 for sarcopenia. The central experiments were cell-based, and the available evidence does not provide oral aged-mouse dose details or human functional outcomes. High-dose vitamin B6 can also cause harm; a cell-culture concentration is not a supplement label.

The relevant elderly NR trial found no muscle benefit

The clearest human warning comes from a randomized, placebo-controlled JCI Insight trial in older adults. Thirty-one completers took NR 1,000 mg/day plus pterostilbene 200 mg/day, or placebo, for 14 days before electrostimulation-induced muscle injury. Adherence was about 96%, and whole-blood NAD+, NAAD, and Me₂/4PY increased, confirming that participants absorbed the supplement.

Eight days after injury, muscle stem-cell content had increased 107% from baseline in both groups. NR plus pterostilbene did not improve that response versus placebo (P=0.58), nor did it improve maximal voluntary contraction, rate of force development, muscle-fiber area, central nuclei, or embryonic myosin heavy-chain expression. Most important, supplementation did not raise skeletal-muscle NAD+; injury itself did.

The trial was small, the 14-day lead-in may have been too short, and an electrostimulation injury model validated in younger men may not behave the same way in older adults. Participants also did not have a baseline run-in biopsy confirming an NAD+ deficit. Those limits could hide a modest effect, but they do not erase the compartment problem: a higher blood NAD+ level did not demonstrate delivery to aging muscle.

NMN can reach muscle in one setting, but sarcopenia remains untested

NMN should not be grouped automatically with NR. In a 10-week, randomized, double-blind, placebo-controlled Science trial, NMN increased skeletal-muscle insulin sensitivity and muscle NAD+ in overweight or obese postmenopausal women with prediabetes. That population did not have established sarcopenia, and the endpoint was metabolic insulin sensitivity rather than muscle mass, strength, or physical function.

A 2026 systematic review and meta-analysis of nine NMN randomized trials involving 412 middle-aged and older participants concluded that NMN's effects on muscle and liver function remain unclear. The evidence therefore supports a narrower conclusion: NMN can affect muscle biology in some people, but it has not established a clinical role in sarcopenia.

NR may also help in a very different disease context. A double-blind crossover trial in Werner syndrome, a rare premature-aging condition, reported benefits with NR, but that does not answer whether NR prevents ordinary age-related muscle loss in older adults. Disease biology, baseline NAD+ depletion, and the measured outcomes all differ.

What deserves attention now

If the goal is stronger, more functional muscle, resistance training has the better human evidence. A 2024 meta-analysis of 13 randomized trials in 2,080 adults over 70 with sarcopenia found that more than 10 weeks of resistance training improved handgrip strength by 1.67 kg, isometric strength (standardized mean difference 0.53), chair-stand performance (SMD 0.40), and skeletal-muscle mass index by 1.67 kg/m². Protein alongside training also has a meaningful trial literature, including a systematic review in sarcopenic older adults.

NAD+ precursors are a research category, not a substitute for progressive resistance training, adequate protein, or evaluation for medical causes of weakness and weight loss.

Trigonelline is the most intriguing lead because sarcopenic people have lower circulating levels and because its pathway may bypass a bottleneck in aging muscle. NAM plus pyridoxine offers a second, mechanistically distinct lead from human stem-cell experiments. Neither has demonstrated that supplementation improves sarcopenia in people. NR plus pterostilbene has the most directly relevant elderly intervention trial, and it was null despite higher blood NAD+.

For now, the right question is not which NAD+ bottle has the most convincing marketing. It is whether a precursor reaches skeletal muscle, raises NAD+ there, and then improves strength or function in people with sarcopenia. No precursor has yet checked all three boxes.